MODIFIED BOUGANIN PROTEINS, CYTOTOXINS AND METHODS AND USES THEREOF
The invention provides modified forms of bouganin protein having biological activity and a reduced propensity to activate human T cells as compared to the non-modified bouganin protein. The invention also provides T-cell epitope peptides of bouganin, and modified T-cell epitope peptides of bouganin...
Gespeichert in:
| Hauptverfasser: | , , , , , , , |
|---|---|
| Format: | Patent |
| Sprache: | eng ; por |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | GLEN CHRISTOPHER MACDONALD FRANCIS J. CARR JEANNICK CIZEAU KOEN HELLENDOORN DENIS GEORGES BOSC NICHOLAS RONALD GLOVER JOYCELYN ENTWISTLE MATTHEW BAKER |
| description | The invention provides modified forms of bouganin protein having biological activity and a reduced propensity to activate human T cells as compared to the non-modified bouganin protein. The invention also provides T-cell epitope peptides of bouganin, and modified T-cell epitope peptides of bouganin which have a reduced propensity to activate human T cells as compared to the non-modified T-cell epitope peptide. The invention also provides cytotoxins having the having a ligand that binds to a cancer cells attached to the modified bouganin proteins. Also provided are methods of inhibiting or destroying mammalian cancer cells using the cytotoxins of the invention and pharmaceutical compositions for treating human cancer. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_PT1737961EE</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>PT1737961EE</sourcerecordid><originalsourceid>FETCH-epo_espacenet_PT1737961EE3</originalsourceid><addsrcrecordid>eNrjZHD29XfxdPN0dVFw8g91d_Tz9FMICPIPcfX0C9ZRcI4M8Q_xjwCyFRz9XBR8XUM8_F0g7NBg12CFEA_XIFd_Nx4G1rTEnOJUXijNzaDg5hri7KGbWpAfn1pckJicmpdaEh8QYmhubG5pZujqakyEEgDrayuD</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>MODIFIED BOUGANIN PROTEINS, CYTOTOXINS AND METHODS AND USES THEREOF</title><source>esp@cenet</source><creator>GLEN CHRISTOPHER MACDONALD ; FRANCIS J. CARR ; JEANNICK CIZEAU ; KOEN HELLENDOORN ; DENIS GEORGES BOSC ; NICHOLAS RONALD GLOVER ; JOYCELYN ENTWISTLE ; MATTHEW BAKER</creator><creatorcontrib>GLEN CHRISTOPHER MACDONALD ; FRANCIS J. CARR ; JEANNICK CIZEAU ; KOEN HELLENDOORN ; DENIS GEORGES BOSC ; NICHOLAS RONALD GLOVER ; JOYCELYN ENTWISTLE ; MATTHEW BAKER</creatorcontrib><description>The invention provides modified forms of bouganin protein having biological activity and a reduced propensity to activate human T cells as compared to the non-modified bouganin protein. The invention also provides T-cell epitope peptides of bouganin, and modified T-cell epitope peptides of bouganin which have a reduced propensity to activate human T cells as compared to the non-modified T-cell epitope peptide. The invention also provides cytotoxins having the having a ligand that binds to a cancer cells attached to the modified bouganin proteins. Also provided are methods of inhibiting or destroying mammalian cancer cells using the cytotoxins of the invention and pharmaceutical compositions for treating human cancer.</description><language>eng ; por</language><subject>BEER ; BIOCHEMISTRY ; CHEMISTRY ; COMPOSITIONS THEREOF ; CULTURE MEDIA ; ENZYMOLOGY ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; MICROBIOLOGY ; MICROORGANISMS OR ENZYMES ; MUTATION OR GENETIC ENGINEERING ; ORGANIC CHEMISTRY ; PEPTIDES ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS ; SPIRITS ; VINEGAR ; WINE</subject><creationdate>2013</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20130826&DB=EPODOC&CC=PT&NR=1737961E$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25543,76293</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20130826&DB=EPODOC&CC=PT&NR=1737961E$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>GLEN CHRISTOPHER MACDONALD</creatorcontrib><creatorcontrib>FRANCIS J. CARR</creatorcontrib><creatorcontrib>JEANNICK CIZEAU</creatorcontrib><creatorcontrib>KOEN HELLENDOORN</creatorcontrib><creatorcontrib>DENIS GEORGES BOSC</creatorcontrib><creatorcontrib>NICHOLAS RONALD GLOVER</creatorcontrib><creatorcontrib>JOYCELYN ENTWISTLE</creatorcontrib><creatorcontrib>MATTHEW BAKER</creatorcontrib><title>MODIFIED BOUGANIN PROTEINS, CYTOTOXINS AND METHODS AND USES THEREOF</title><description>The invention provides modified forms of bouganin protein having biological activity and a reduced propensity to activate human T cells as compared to the non-modified bouganin protein. The invention also provides T-cell epitope peptides of bouganin, and modified T-cell epitope peptides of bouganin which have a reduced propensity to activate human T cells as compared to the non-modified T-cell epitope peptide. The invention also provides cytotoxins having the having a ligand that binds to a cancer cells attached to the modified bouganin proteins. Also provided are methods of inhibiting or destroying mammalian cancer cells using the cytotoxins of the invention and pharmaceutical compositions for treating human cancer.</description><subject>BEER</subject><subject>BIOCHEMISTRY</subject><subject>CHEMISTRY</subject><subject>COMPOSITIONS THEREOF</subject><subject>CULTURE MEDIA</subject><subject>ENZYMOLOGY</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>MICROBIOLOGY</subject><subject>MICROORGANISMS OR ENZYMES</subject><subject>MUTATION OR GENETIC ENGINEERING</subject><subject>ORGANIC CHEMISTRY</subject><subject>PEPTIDES</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><subject>SPIRITS</subject><subject>VINEGAR</subject><subject>WINE</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2013</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZHD29XfxdPN0dVFw8g91d_Tz9FMICPIPcfX0C9ZRcI4M8Q_xjwCyFRz9XBR8XUM8_F0g7NBg12CFEA_XIFd_Nx4G1rTEnOJUXijNzaDg5hri7KGbWpAfn1pckJicmpdaEh8QYmhubG5pZujqakyEEgDrayuD</recordid><startdate>20130826</startdate><enddate>20130826</enddate><creator>GLEN CHRISTOPHER MACDONALD</creator><creator>FRANCIS J. CARR</creator><creator>JEANNICK CIZEAU</creator><creator>KOEN HELLENDOORN</creator><creator>DENIS GEORGES BOSC</creator><creator>NICHOLAS RONALD GLOVER</creator><creator>JOYCELYN ENTWISTLE</creator><creator>MATTHEW BAKER</creator><scope>EVB</scope></search><sort><creationdate>20130826</creationdate><title>MODIFIED BOUGANIN PROTEINS, CYTOTOXINS AND METHODS AND USES THEREOF</title><author>GLEN CHRISTOPHER MACDONALD ; FRANCIS J. CARR ; JEANNICK CIZEAU ; KOEN HELLENDOORN ; DENIS GEORGES BOSC ; NICHOLAS RONALD GLOVER ; JOYCELYN ENTWISTLE ; MATTHEW BAKER</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_PT1737961EE3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; por</language><creationdate>2013</creationdate><topic>BEER</topic><topic>BIOCHEMISTRY</topic><topic>CHEMISTRY</topic><topic>COMPOSITIONS THEREOF</topic><topic>CULTURE MEDIA</topic><topic>ENZYMOLOGY</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>MICROBIOLOGY</topic><topic>MICROORGANISMS OR ENZYMES</topic><topic>MUTATION OR GENETIC ENGINEERING</topic><topic>ORGANIC CHEMISTRY</topic><topic>PEPTIDES</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><topic>SPIRITS</topic><topic>VINEGAR</topic><topic>WINE</topic><toplevel>online_resources</toplevel><creatorcontrib>GLEN CHRISTOPHER MACDONALD</creatorcontrib><creatorcontrib>FRANCIS J. CARR</creatorcontrib><creatorcontrib>JEANNICK CIZEAU</creatorcontrib><creatorcontrib>KOEN HELLENDOORN</creatorcontrib><creatorcontrib>DENIS GEORGES BOSC</creatorcontrib><creatorcontrib>NICHOLAS RONALD GLOVER</creatorcontrib><creatorcontrib>JOYCELYN ENTWISTLE</creatorcontrib><creatorcontrib>MATTHEW BAKER</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>GLEN CHRISTOPHER MACDONALD</au><au>FRANCIS J. CARR</au><au>JEANNICK CIZEAU</au><au>KOEN HELLENDOORN</au><au>DENIS GEORGES BOSC</au><au>NICHOLAS RONALD GLOVER</au><au>JOYCELYN ENTWISTLE</au><au>MATTHEW BAKER</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>MODIFIED BOUGANIN PROTEINS, CYTOTOXINS AND METHODS AND USES THEREOF</title><date>2013-08-26</date><risdate>2013</risdate><abstract>The invention provides modified forms of bouganin protein having biological activity and a reduced propensity to activate human T cells as compared to the non-modified bouganin protein. The invention also provides T-cell epitope peptides of bouganin, and modified T-cell epitope peptides of bouganin which have a reduced propensity to activate human T cells as compared to the non-modified T-cell epitope peptide. The invention also provides cytotoxins having the having a ligand that binds to a cancer cells attached to the modified bouganin proteins. Also provided are methods of inhibiting or destroying mammalian cancer cells using the cytotoxins of the invention and pharmaceutical compositions for treating human cancer.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng ; por |
| recordid | cdi_epo_espacenet_PT1737961EE |
| source | esp@cenet |
| subjects | BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS THEREOF CULTURE MEDIA ENZYMOLOGY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS SPIRITS VINEGAR WINE |
| title | MODIFIED BOUGANIN PROTEINS, CYTOTOXINS AND METHODS AND USES THEREOF |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T11%3A06%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=GLEN%20CHRISTOPHER%20MACDONALD&rft.date=2013-08-26&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EPT1737961EE%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |